anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tumor malignant cells are characterized by dysregulation of mitochondrial bioenergetics due to the 'Warburg effect'. In the present study, this metabolic imbalance was explored as a potential target for novel cancer chemotherapy. Imatinib (IM) downregulates the expression levels of SCΟ2 and FRATAXIN (FXN) genes involved in the heme‑dependent cytochrome c oxidase biosynthesis and assembly pathway in human erythroleukemic IM‑sensitive K‑562 chronic myeloid leukemia cells (K‑562). In the present study, it was investigated whether the treatment of cancer cells with IM (an inhibitor of oxidative phosphorylation) separately, or together with dichloroacetate (DCA) (an inhibitor of glycolysis), can inhibit cell proliferation or cause death. Human K‑562 and IM‑chemoresistant K‑562 chronic myeloid leukemia cells (K‑562R), as well as human colorectal carcinoma cells HCT‑116 (+/+p53) and (‑/‑p53, with double TP53 knock-in disruptions), were employed. Treatments of these cells with either IM (1 or 2 µM) and/or DCA (4 mΜ) were also assessed for the levels of several process biomarkers including SCO2, FXN, lactate dehydrogenase A, glyceraldehyde‑3‑phosphate dehydrogenase, pyruvate kinase M2, hypoxia inducing factor‑1a, heme oxygenase‑1, NF‑κB, stem cell factor and vascular endothelial growth factor via western blot analysis. Computational network biology models were also applied to reveal the connections between the ten proteins examined. Combination treatment of IM with DCA caused extensive cell death (>75%) in K‑562 and considerable (>45%) in HCT‑116 (+/+p53) cultures, but less in K‑562R and HCT‑116 (‑/‑p53), with the latter deficient in full length p53 protein. Such treatment, markedly reduced reactive oxygen species levels, as measured by flow‑cytometry, in K‑562 cells and affected the oxidative phosphorylation and glycolytic biomarkers in all lines examined. These findings indicated, that targeting of cancer mitochondrial bioenergetics with such a combination treatment was very effective, although chemoresistance to IM in leukemia and the absence of a full length p53 in colorectal cells affected its impact.
The open Folium hydrangeae strigosae with preventing and treating sucutaneous nodule effect of the present invention and preparation method, this Folium hydrangeae strigosae uses Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz., Herba Fici Simplicissimae, Involucrum Castaneae, gloiopeltis, Fructus Akebiae, Semen Citri Reticulatae, Radix ipomoeae aquaticae, Folium et Cacumen Artemisiae Halodendri seed and EM original solution etc. to be prepared from.Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz. clearing heat, detoxicating, dispelling dampness is subsided a swelling, also has the effect that anti-inflammatory and antalgic protects the liver, clearing heat, detoxicating, dispelling dampness detumescence effect is enhanced together with Herba Fici Simplicissimae, gloiopeltis, Herba Rabdosiae glaucocalycis and Radix ipomoeae aquaticae etc., gloiopeltis resolving phlegm and softening hard masses, nourishing stomach and spleen, Semen Citri Reticulatae is regulated the flow of vital energy, removing obstruction for relieving pain, and all things share interpromoting relation in five elements help and play the good effect that medicine is bigger.Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz. and Herba Fici Simplicissimae sweet in the mouth fragrance, cover neutralization Semen Citri Reticulatae and the bitter taste of foxtail millet ball top.EM original solution anti-inflammation and sterilization, except stench abnormal flavour, anti-corrosive fresh-keeping, decomposes poisonous and harmful substance, strengthens gastrointestinal and resists disease ability.Folium hydrangeae strigosae is sweet, and prevention effect is definite, and low price, the easy people that draw materials like often to drink.
Thirty six patients who underwent HSCT for hematologic malignancies, and received myeloablative conditioning, without prophylactic antibiotics, between 2013-2017 enrolled in the Aflac biorepository will comprise the comparison arm. Clinical data on transplant and infection characteristics is available and linked to stool microbiome samples already analyzed and described. Stored plasma and peripheral blood mononuclear cells are available for further analysis.
The invention discloses a kind of hand-held diabetes management equipment with data base management system. This equipment comprises multiple input modules, and the plurality of input module comprises blood sugar reader, user interface, communication interface and continuous blood sugar input module. Input module output is used for the data of the data record that generates different record types. This equipment further comprises N database, each database has different frequency scope associated therewith, wherein, the frequency range of certain database of new record based in a described N database and the frequency of specific record type and be stored in described certain database, and N is greater than 1 integer. This equipment is further included in the database manipulation module of performing database operation on a described N database. Described data base management system provides in the reliability that keeps it to carry out the raising aspect recording of decision important in medical treatment.
Although medications for opioid use disorders (MOUD) is safe and effective and is currently considered the gold standard for treating OUD, adherence to MOUD regimens remains a challenge. Early studies have demonstrated efficacy of mindfulness-based interventions as adjunctive treatment for substance use disorders (SUD) while reducing substance use and cravings. In addition, non-randomized pilot studies suggest that mindfulness-based interventions may be effective in reducing symptoms of depression and anxiety in individuals undergoing MOUD.

The goal of the proposed study is to determine the effectiveness of a mindfulness-based intervention that also utilizes peer mentors in addition to professional substance abuse therapists (the Minds and Mentors program \[MiMP\]) in improving adherence to MOUD and reducing relapse rates in a sample of individuals with OUD who are also on MOUD versus a twelve-step facilitation (TSF) program. The MiMP is a twelve-week intervention that uses group therapy and meets once a week for about two hours. The primary outcome measure will is adherence to medications for OUD. The secondary outcome measures will include the demographic covariates, depression, anxiety, stress, quality of life, and cravings. Finally, exploratory outcome measures will include cortisol levels and rates of reactivity to drug cues. This study will randomize participants in either intervention or control group in blocks of five. Data collection will occur at baseline, 8 weeks, 12 weeks (end of treatment) and at 12- week and 24- week follow-up.
Bruton's tyrosine kinase (BTK) is central to the survival of malignant and normal B lymphocytes and has been a crucial therapeutic target of several generations of kinase inhibitors and newly developed degraders. These new means for targeting BTK have added additional agents to the armamentarium for battling cancers dependent on B-cell receptor (BCR) signaling, including chronic lymphocytic leukemia and other non-Hodgkin lymphomas. However, the development of acquired resistance mutations to each of these classes of BTK inhibitors has led to new challenges in targeting BTK as well as novel insights into BCR signaling. The first-generation covalent BTK inhibitor ibrutinib is susceptible to mutations affecting the covalent binding site, cysteine 481 (C481). Newer noncovalent BTK inhibitors, such as pirtobrutinib, overcome C481 mutation-mediated resistance but are susceptible to other kinase domain mutations, particularly at residues Threonine 474 and Leucine 528. In addition, these novel BTK inhibitor resistance mutations have been shown biochemically and in patients to cause cross-resistance to some covalent BTK inhibitors. Importantly, newer generation covalent BTK inhibitors zanubrutinib and acalabrutinib are susceptible to the same mutations that confer resistance to noncovalent inhibitors. The BTK L528W mutation is of particular interest as it disrupts the kinase activity of BTK, rendering it kinase dead. This observation suggests that BTK may act independently of its kinase activity as a scaffold. Thus, the timely development of BTK degrading proteolysis targeting drugs has allowed for degradation, rather than just enzymatic inhibition, of BTK in B-cell lymphomas, and early clinical trials to evaluate BTK degraders are underway.
Cryptosporidium parvum  is a highly prevalent zoonotic and anthroponotic protozoan parasite that causes a diarrheal syndrome in children and neonatal livestock, culminating in growth retardation and mortalities. Disclosed herein are inhibitors against the enzymatic activity of recombinant CpLDH protein that were identified. The inhibitors were tested for anti- Cryptosporidium  effect using  in vitro  infection assays of HCT-8 cells monolayers. Compounds NSC158011 and NSC10447 were identified to inhibit the proliferation of intracellular C.  parvum in vitro , with IC50 values of 14.88 and 72.65 μM, respectively. At doses tolerable in mice, both NSC158011 and NSC10447 significantly reduced the shedding of C.  parvum  oocysts in infected immunocompromised mice's feces and prevented intestinal villous atrophy as well as mucosal erosion due to C.  parvum . These findings have unveiled anti- Cryptosporidium  drug candidates that can be explored further for the development of therapeutic agents against C.  parvum  infections.
PURPOSE: A pharmaceutical composition containing a compound isolated from Rumex japonicas for preventing and treating cancer is provided to effectively induce apoptosis without side effects. CONSTITUTION: An 8-O-glucose musizin of chemical formula 1 is a compound isolated from Rumex japonicas. A method for isolating 8-O-glucose musizin comprises: a step of extracting dried Rumex japonicas with solvent; a step of filtering the extract and concentrating; and a step of purifying through chromatography. The extraction solvent is methanol, ethanol, isopropanol, ethyleneglycol, THF, DMF, DMSO, or ethyleneacetate. A composition for anti-cancer contains the 8-O-glucose musizin as an active ingredient. A pharmaceutical composition for preventing and treating cancer contains the composition and pharmaceutically acceptable carrier.
Drug addiction is a chronic, devastating, but treatable disorder, for which there exists a growing armamentarium of evidence-based interventions, including pharmacotherapies and psychotherapies. A core principle of drug addiction treatment, however, states that no single treatment is appropriate for everyone; rather, treatments need to be adjusted based on patient characteristics and response in order to be maximally effective. Ideally, clinicians would identify a sequence of interventions that works best across different stages of addiction treatment, from abstinence initiation to relapse prevention. Adaptive treatment interventions have been used successfully to inform this sequential clinical decision-making process. For cocaine use disorders (CUD), the most potent intervention currently available for initiating abstinence is behavior therapy using contingency management (CM) procedures. Intensive CM has been shown to produce initial cocaine abstinence rates of 40%, unmatched by all other forms of behavioral or pharmacological treatment, making it a prototypical first-line therapy for CUD. Importantly, achievement of initial abstinence predicts future abstinence. For the clinician, these research findings translate into a straightforward question: Can the investigators drive CM response rates even higher with targeted adjunctive interventions?

The proposed sequential, multiple assignment, randomized trial (SMART) will provide the data needed to answer this question. First, the investigators will determine whether Acceptance and Commitment Therapy (ACT) in combination with CM increases initial treatment response rates. The investigators hypothesize that four weeks of treatment with ACT+CM will produce higher abstinence rates than initial treatment combining standard Drug Counseling with CM (DC+CM). The hypothesized synergism of ACT+CM on primary treatment mechanisms of experiential avoidance and reward sensitivity, respectively, will be examined. Second, for patients who do not respond to initial treatment, the investigators will examine whether dopamine-targeted pharmacotherapy is an effective augmentation strategy. Specifically, the investigators hypothesize that continued ACT+CM treatment with modafinil augmentation will be most effective in promoting abstinence relative to treatment combinations involving continued DC and/or placebo. Third, for patients who respond to initial treatment, the investigators will assess the relative benefit of continued treatment with ACT+CM, as compared to DC+CM, to prevent relapse. ACT emphasizes goal-directed actions based on values that are intrinsically motivating, and is thereby expected to be a more effective intervention for extending the duration of abstinence following initial treatment with intensive CM.
Risk Summary

There are no available data on ELFABRIO use in pregnant females to evaluate a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes; however, as an enzyme replacement, ELFABRIO is not expected to cause adverse outcomes. Animal reproduction studies have been conducted with pegunigalsidase alfa-iwxj in pregnant rats and rabbits. No adverse effects on embryofetal development were observed in pregnant rats intravenously administered pegunigalsidase alfa-iwxj twice per week at exposures up to 3.6 times that of the maximum recommended human dose (MRHD) (based on area under the concentration-time curve (AUC)). Maternal toxicity was observed in pregnant rabbits intravenously administered pegunigalsidase alfa-iwxj twice per week at doses that were ≥ 3.2 times the MRHD (based on human equivalent dose) [see Data].

The estimated background risk of major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

There is a pregnancy safety study for ELFABRIO. If a patient becomes pregnant while receiving ELFABRIO, healthcare providers should report ELFABRIO exposure by calling 1-888-661-9260 or visiting https://chiesirarediseases.com/contact-us/medical-information-form.

Data

Animal Data

In an embryofetal development study in the rat, pegunigalsidase alfa-iwxj was administered during the period of organogenesis on gestation day 6, 9, 12, and 15. No maternal or fetal adverse effects were noted at exposures that were up to 3.6-fold greater than the recommended dose of 1 mg/kg every two weeks.

In an embryofetal development study in the rabbit, administration of pegunigalsidase alfa-iwxj during the period of organogenesis on gestation day 6, 9, 12, 15, and 18, resulted in maternal toxicity, including maternal mortality, decreased body weight, and decreased feed consumption. These effects were observed at exposures that were ≥ 3.2-fold greater than the recommended dose of 1 mg/kg every two weeks. Adverse embryofetal effects included abortion, increased late resorptions, number of does with resorptions, and increased post-implantation loss at exposures that were 6.5 fold greater than the recommended dose of 1 mg/kg every two weeks. Decreased fetal body weight was observed at exposures that were ≥ 3.2 times greater than the recommended dose of 1 mg/kg every two weeks. There was no increase in fetal external, skeletal, or visceral malformations.
CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10 one-hour sessions intervention format. Participants randomized to the CO-OP group will continue to receive usual out-patient services, such as physiotherapy or speech-language therapy, but will receive CO-OP instead of usual occupational therapy.
Anemia in newborn babies is defined as the mean of hemoglobin values according to postnatal age is below 2 standard deviations. Disruption in tissue perfusion and oxygenation, hyperdynamic cardiac failure, increase in need of oxygen, increase in respiratory effort, inability to be separated from mechanical ventilation, failure to thrive, paleness, increase in frequency of morbidities of prematurity (necrotizing enterocolitis, retinopathy of prematurity, intraventricular hemorrhage, etc.) may be seen as a result of progressive anemia. When critical hemoglobin values are reached in premature newborn babies with concomitant disruption of tissue oxygenation, transfusion is performed with erythrocyte suspensions. The main goal here is to correct impaired tissue oxygenation, provide perfusion in sufficient quantity, and prevent anemia-related morbidities. Although frequently applied, there is no consensus in our country and in the world regarding threshold hemoglobin values and supporting parameters for transfusions. As a result, there are no guidelines prepared for newborns based on evidence with clearly defined borders and accepted by everyone. Many countries and centers implement different transfusion protocols based on their experience. Given the risk of oxygen radical damage and associated diseases as a result of erythrocyte transfusions (infections, bone marrow suppression, necrotizing enterocolitis, retinopathy of prematurity, etc.), there is a need to develop new methods for taking and supporting transfusion decision, and to prepare more objective and more accepted guidelines. The origin of our study is the subsequent protective compensation mechanisms after deterioration in brain oxygenation due to symptomatic anemia in premature newborn babies. For these reasons, it is aimed to examine the changes in brain blood supply and oxygenation in neonatal premature babies who have anemia and who underwent erythrocyte suspension transfusion in the light of original guidelines by means of obtaining measurements with the help of cranial doppler ultrasonography and near-infrared spectroscopy.
1. An aqueous pharmaceutical composition containing ciclesonide and hydroxypropylmethylcellulose, wherein said ciclesonide is dispersed in an aqueous medium in form of solid particles. 2. An aqueous pharmaceutical composition according to claim 1 wherein said hydroxypropylmethylcellulose concentration is from 0.01% w/w to 30% w/w, relative to the total amount of the composition. 3. An aqueous pharmaceutical composition according to claim 1 wherein said hydroxypropylmethylcellulose concentration is from 0.01% w/w to 5% w/w, relative to the total amount of the composition. 4. An aqueous pharmaceutical composition according to claim 1 wherein said hydroxypropylmethylcellulose concentration is from 0.01% w/w to 1% w/w, relative to the total amount of the composition. 5. An aqueous pharmaceutical composition according to claim 1 wherein said hydroxypropylmethylcellulose concentration is from 0.01% w/w to 0.5% w/w, relative to the total amount of the composition. 6. An aqueous pharmaceutical composition according to any of claims 1 through 5 additionally containing one or more types of a water-insoluble substance and/or water-low soluble substance. 7. An aqueous pharmaceutical composition according to claim 6 wherein said water-insoluble substance and/or water-low soluble substance is a cellulose. 8. An aqueous pharmaceutical composition according to claim 7 wherein said cellulose is crystalline cellulose. 9. An aqueous pharmaceutical composition according to any of claims 1 through 8 additionally containing water-soluble polymer substance. 10. An aqueous pharmaceutical composition according to claim 9 wherein said water-soluble polymer substance is one or more types selected from the group consisting of polyethylene glycol, propylene glycol alginate, pectin, low methoxyl pectin, gua gum, gum arabic, carrageenan, methylcellulose, carboxymethylcellulose sodium, xanthan gum and hydroxypropylcellulose. 11. An aqueous pharmaceutical composition according to claim 9 wherein said water-soluble polymer substance is carboxymethylcellulose sodium. 12. An aqueous pharmaceutical composition according to claim 9 wherein said water-soluble polymer substance is polyethylene glycol. 13. An aqueous pharmaceutical composition according to claim 9 wherein said water-soluble polymer substance is hydroxypropylcellulose. 14. An aqueous pharmaceutical composition according to any of claims 1 through 13 wherein the combination of said water-insoluble substance and said water-soluble polymer substance is crystalline cellulose carmellose sodium.
The present invention provides a medical image management system and method that uses a central data management system to centrally manage the storage and transmission of electronic records containing medical images between remotely located facilities. The present invention also provides a system and method for packaging an image for secure transmission. The present invention also provides a system for tracking delivery and review of images and various attachments or augmentations to the image files. The invention also provides a system and method for providing lifetime storage of images that may be accessed by different authorized imaging centers and providers throughout the life of the patient. An image or file is packaged to be transmitted through a firewall of an image viewing location and stored in a relational database at the remote viewer. The image is delivered to a physician for ready accessibility at a remote viewer. Various files may be added to the patient's file at remote viewers. Overlays, reports and other attachments are created or input at image viewing stations and may packaged for delivery to authorized locations and are tracked and stored by a data center.
The invention belongs to the technical field of medicine and particularly relates to a traditional Chinese medicine composition for treating heart-spleen deficiency type hyperthyroidism complicating automatic junctional tachycardia. The traditional Chinese medicine composition is prepared from, by weight, 4-8 parts of grifola frondosa flowers, 4-8 parts of parish's ironweed, 4-8 parts of triplostegia glandulifera Wall. ex DC., 4-8 parts of seeds of thuja koraiensis nakai, 4-8 parts of all grass of aletris spicata, 4-8 parts of ficus fulva, 4-8 parts of rhizomes of satyrium henryi schlecht, 4-8 parts of herb of nutgrass galingale, 4-8 parts of roots of oblique rhychoglossum, 4-8 parts of herb of creeping rattlesnake plantain, 4-8 parts of celastrus flagellaris Rupr. fruits, 4-8 parts of dragon's teeth and 4-8 parts of liquorice roots. All the herbs are combined to jointly achieve the effects of strengthening the spleen, nourishing the heart, invigorating qi and blood, resolving hardness to dissipate stagnation, and tranquilizing the mind by soothing the heart. The average heart rate can be reduced, the thyroid function level can be recovered, the safety index is not affected, and safety is good.
After completion maximal safe surgical resection, patients undergo radiation therapy for 42 days, initiating whole brain radiation therapy at day 21 (dose 16 of radiation therapy) and receive temozolomide daily on days 1 to 42. Beginning 7 days before the completion of whole brain radiation therapy, patients receive plerixafor by continuous infusion on days to 1 to 28. Beginning 1 week after completion of plerixafor infusion and 35 days after completion of whole brain radiation therapy, patients receive temozolomide monthly for 6 to 12 courses in the absence of disease progression or unacceptable toxicity.